CompletedNCT00341328Updated Apr 26, 2013

Efficacy and Safety of Immunomodulator as an Adjunct Therapy in New Pulmonary Tuberculosis(Category I) Patients.

A Phase 3 interventional study of Intradermal injection of Mycobacterium w in Tuberculosis, sponsored by Ministry of Science and Technology, India. Completed at 2 sites in India. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2013-04-26.

Sponsored by Ministry of Science and Technology, India · Phase 3, Interventional, and Treatment

Phase: Phase 3
Study type: Interventional
Enrollment: 300
Allocation: Randomized
Ages: 18 Years to 60 Years
Sex: All

Study summary

The purpose of the study is to evaluate the efficacy and safety of Mycobacterium w in new lung tuberculosis patients. Mycobacterium w is a strain of bacterium which is being used as vaccine and adjunct drug against leprosy. This agent has also been found to be useful in the treatment of lung tuberculosis in limited number of patients.

We are conducting this study in category-I patients( As per World Health Organization,Geneva classification of tuberculosis) having lung tuberculosis to see the efficacy and also to see any change in the immunological parameters.

Read the detailed description

Mycobacterium w is a recently introduced immunomodulator ,which has been found to be useful in rapid killing of Mycobacterium leprae. It improves clearance of Mycobacterium leprae from body and is thereby useful in reducing duration of therapy significantly for multibacillary leprosy. Mycobacterium w shares antigens with Mycobacterium leprae as well as Mycobacterium tuberculosis. Mycobacterium w is also found to be useful in prevention of tuberculosis in experimental animals. Previous studies for efficacy of Mycobacterium w as immunomodulator in pulmonary tuberculosis patients have shown faster sputum conversion rates in patients given Mycobacterium w as an adjuvant therapy along with standard anti-tuberculosis treatment. It has faster and remarkable sputum converting capacity. Similar studies conducted in pulmonary TB category -II [Re-treatment as per Revised National Tuberculosis Control Programme (RNTCP), Govt. of India] patients have shown improved cure rates.

Mycobacterium w is commercially available under the brand name of "Immuvac" injection in 0.5 ml multi-dose vials approved for use as immunomodulator against Mycobacterium leprae in patients with leprosy. Each vial has 500 million heat-killed bacilli in a buffered solution. It is manufactured by Cadila Pharmaceuticals Ltd.; Ahmedabad, Gujarat-382 210, India. In this clinical trial one dose consists of 0.1 ml given as intradermal injection, which contains 100 million bacilli. A total of 6 doses are given during the Intensive Phase(as per RNTCP,Ministry of Health and Family Welfare,Govt.of India) of treatment. Two injections on both upper arms on day-0 and subsequently one injection on days 14,28,42 and 56. No injections are given during the Continuation Phase(as per RNTCP,Ministry of Health and Family Welfare,Govt.of India)of treatment.

As of now it is not commercially available for therapeutic use in TB patients as immunomodulator.Therefore we are investigating Mycobacterium w for its efficacy in TB patients in a "double-blind placebo-controlled randomized clinical control trial" fashion. We are conducting this trial in Category-I pulmonary TB Patients(as per RNTCP,Ministry of Health and Family Welfare,Govt.of India),and are assessing the outcome in the form of clinical improvement,sputum conversion and immunological parameters. This is a multi-centric trial sponsored by the Department of Biotechnology, Ministry of Science and Technology, Govt. of India and Cadila Pharmaceuticals Ltd., India.

Conditions studied

Tuberculosis

Browse trials for

Keywords

India
Pulmonary Tuberculosis
Category-I Pulmonary Tuberculosis
Immunomodulator
Mycobacterium w

In context

Tuberculosis

1,417 studies on the registry are indexed under Tuberculosis; 208 are open to participants now.

This study's enrollment of 300 is above the median of 150 across 952 interventional studies indexed under Tuberculosis.

Browse Tuberculosis studies →

Lead sponsor

Ministry of Science and Technology, India is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years to 60 Years
Sexes eligible: All
Accepts healthy volunteers: No

Inclusion criteria

Patients of either sex aged between 18 to 60 yrs.
Newly diagnosed sputum positive pulmonary TB cases with at least 2 sputum samples that are positive on sputum microscopy (Negative, Scanty, Scanty may be enrolled.
Patients who are willing to give an informed consent.

Exclusion criteria

Exclusion Criteria

Known hypersensitivity to Category I anti-TB drugs on history at the time of Screening.
Known history of DR-TB (includes MDR-TB and XDR-TB) at the time of screening. Patients with Mtb isolate resistant to one or more drugs are to be excluded.
Presence of secondary immunodeficiency states: HIV, organ transplantation, diabetes mellitus, malignancy, treatment with corticosteroids (illicited on detailed history and lab investigations).
Hepatitis B and C positivity.
Patients with known extrapulmonary TB and/or patients requiring surgical intervention.
Currently receiving cytotoxic therapy, or have received it within the last 3 months- Ask on History.
Pregnancy and lactation on history.
Patients with a known seizure disorder on history.
Patients with known symptomatic cardiac disease, such as arrhythmias or coronary artery disease on history.
Patients with abnormal renal function (Serum creatinine more than 1.5 or proteinuria more than 2+ )
Patients with abnormal hepatic functions (bilirubin = 1.5 mg/dl; AST, ALT, SAP more than 1.5 x ULN; PT = 1.3x control)
Patients with hematological abnormalities (WBC lesser than or equal to 3000/mm3; platelets less than or equal to 100,000/mm3).
Seriously ill and moribund patients with complications:
1. low lung reserve, marked tachypnoea, chronic cor pulmonale, congestive cardiac failure, BMI\<15,
2. severe hypoalbuminemia (\< 2.5 g/dl).
Patients unlikely to survive for less than 6 months.
Patients unable to comply with the treatment regimen.
Patients with history of alcohol or drug abuse- to be asked for on history and assessed using the CAGE Questions. The patient should be asked four questions in the following manner. A positive response to any of the following questions will be considered an exclusion criterion.
i. Have you ever felt a need to CUT DOWN your drinking?
ii. Have you ever felt ANGRY when confronted about the amount of alcohol you drink?
iii. Have you ever felt GUILTY when confronted about the amount of alcohol you drink?
iv. Have you ever felt the need to have a drink first thing in the morning? (EYE OPENER).

Study design

Phase: Phase 3
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel assignment
Masking: Double (Participant, Investigator)
Enrollment: 300 participants (actual)

Study arms

Experimental
1
In one arm the patient will receive intradermal Mycobacterium W Vaccine along with Category I ATT drugs according to RNTCP guidelines
Biological: Intradermal injection of Mycobacterium w
Placebo comparator
2
In this Arm patient will receive Placebo along with Category I ATT drugs according to RNTCP guidelines
Biological: Intradermal injection of Mycobacterium w

Interventions

BiologicalIntradermal injection of Mycobacterium w
Mw Vaccine is given as intradermal administration. Total 6 doses are given 0.2 ml at baseline and then 0.1 ml after interval of 2 weeks upto 8 weeks
Also known as: Immuvac

What researchers measure

Primary outcomes

The time of sputum conversion as well as the early sputum conversion between the two groups will be evaluated.
Time frame: from the baseline(visit 2)
The cure rate will be evaluated as the primary parameter of efficacy.
Time frame: 6-7 month
The relapse in patients of category-I pulmonary TB will be compared in both the groups.
Time frame: at an interval of 6,12,18 and 24 months after the completion of the therapy
Recording of any clinical adverse reactions for assessment of safety.
Time frame: at anytime during the study

Secondary outcomes

An additional secondary efficacy endpoint is the patient's and physicians's global assessment of the clinical cure.
Time frame: 6-7 month

Study locations

2 sites

All India Institute of Medical Sciences
New Delhi, Delhi 110029, India
Central JALMA Institute of Leprosy and Other Mycobacterial Diseases
Agra, 282001, India

References and documents

Publications

Patel N, Trapathi SB. Improved cure rates in pulmonary tuberculosis category II (retreatment) with mycobacterium w. J Indian Med Assoc. 2003 Nov;101(11):680, 682. PubMed 15198421 ↗
Patel N, Deshpande MM, Shah M. Effect of an immunomodulator containing Mycobacterium w on sputum conversion in pulmonary tuberculosis. J Indian Med Assoc. 2002 Mar;100(3):191-3. PubMed 12408283 ↗
Katoch K, Katoch VM, Natrajan M, Bhatia AS, Sreevatsa, Gupta UD, Sharma VD, Shivannavar CT, Patil MA, Bharadwaj VP. Treatment of bacilliferous BL/LL cases with combined chemotherapy and immunotherapy. Int J Lepr Other Mycobact Dis. 1995 Jun;63(2):202-12. PubMed 7602215 ↗
Sharma P, Mukherjee R, Talwar GP, Sarathchandra KG, Walia R, Parida SK, Pandey RM, Rani R, Kar H, Mukherjee A, Katoch K, Benara SK, Singh T, Singh P. Immunoprophylactic effects of the anti-leprosy Mw vaccine in household contacts of leprosy patients: clinical field trials with a follow up of 8-10 years. Lepr Rev. 2005 Jun;76(2):127-43. PubMed 16038246 ↗
Sharma P, Kar HK, Misra RS, Mukherjee A, Kaur H, Mukherjee R, Rani R. Disabilities in multibacillary leprosy following multidrug therapy with and without immunotherapy with Mycobacterium w antileprosy vaccine. Int J Lepr Other Mycobact Dis. 1999 Sep;67(3):250-8. PubMed 10575404 ↗
Sharma P, Kar HK, Misra RS, Mukherjee A, Kaur H, Mukherjee R, Rani R. Reactional states and neuritis in multibacillary leprosy patients following MDT with/without immunotherapy with Mycobacterium w antileprosy vaccine. Lepr Rev. 2000 Jun;71(2):193-205. doi: 10.5935/0305-7518.20000021. PubMed 10920614 ↗
Sharma P, Misra RS, Kar HK, Mukherjee A, Poricha D, Kaur H, Mukherjee R, Rani R. Mycobacterium w vaccine, a useful adjuvant to multidrug therapy in multibacillary leprosy: a report on hospital based immunotherapeutic clinical trials with a follow-up of 1-7 years after treatment. Lepr Rev. 2000 Jun;71(2):179-92. doi: 10.5935/0305-7518.20000020. PubMed 10920613 ↗
Sharma P, Kar HK, Misra RS, Mukherjee A, Kaur H, Mukherjee R, Rani R. Induction of lepromin positivity following immuno-chemotherapy with Mycobacterium w vaccine and multidrug therapy and its impact on bacteriological clearance in multibacillary leprosy: report on a hospital-based clinical trial with the candidate antileprosy vaccine. Int J Lepr Other Mycobact Dis. 1999 Sep;67(3):259-69. PubMed 10575405 ↗
Sharma SK, Mitra DK, Balamurugan A, Pandey RM, Mehra NK. Cytokine polarization in miliary and pleural tuberculosis. J Clin Immunol. 2002 Nov;22(6):345-52. doi: 10.1023/a:1020604331886. PubMed 12462334 ↗
Khatri GR, Frieden TR. Controlling tuberculosis in India. N Engl J Med. 2002 Oct 31;347(18):1420-5. doi: 10.1056/NEJMsa020098. PubMed 12409545 ↗

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Apr 26, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT00341328
Lead sponsor: Ministry of Science and Technology, India
Responsible party: SK Sharma (Professor and Head, All India Institute of Medical Sciences, New Delhi) — Principal investigator
First posted: Jun 21, 2006
Start date: Mar 2007
Primary completion: Oct 2011
Completion: Mar 2012
Last update: Apr 26, 2013

Study contacts

Surendra K Sharma, MD, Ph.D.

study chair · Professor and Head,Department of Medicine, AIIMS, New Delhi-110029

Bindu Dey, Ph.D.

study director · Department of Biotechnology, MST, GOI

Oversight

Data monitoring committee: Yes

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Tuberculosis→

Other studies from this sponsor

Ministry of Science and Technology, India

Start the discussion